Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap.
amyotrophic lateral sclerosis
cardiac surgery
cardiogenic shock
heart failure
levosimendan
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
05
2021
accepted:
22
07
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
19
1
2022
Statut:
epublish
Résumé
Levosimendan is a distinctive inodilator combing calcium sensitization, phosphodiesterase inhibition and vasodilating properties through the opening of adenosine triphosphate-dependent potassium channels. It was first approved in Sweden in 2000 for the short-term treatment of acutely decompensated severe chronic heart failure when conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. After more than 20 years, clinical applications have considerably expanded across critical care and emergency medicine, and levosimendan is now under investigation in different cardiac settings (eg, septic shock, pulmonary hypertension) and for non-cardiac applications (eg, amyotrophic lateral sclerosis). This narrative review outlines key milestones in levosimendan history, by addressing regulatory issues, pharmacological peculiarities and clinical aspects (efficacy and safety) of a drug that did not receive great attention in the heart failure guidelines. A brief outlook to the ongoing clinical trials is also offered.
Identifiants
pubmed: 34376973
doi: 10.2147/DDDT.S295214
pii: 295214
pmc: PMC8350150
doi:
Substances chimiques
Cardiotonic Agents
0
Phosphodiesterase 3 Inhibitors
0
Vasodilator Agents
0
Simendan
349552KRHK
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3391-3409Informations de copyright
© 2021 Conti et al.
Déclaration de conflit d'intérêts
Professor Emanuel Raschi reports personal fees from Novartis for Consultancy, outside the submitted work. Prof. Dr. Luciano Potena reports personal fees from Novartis, personal fees from Biotest, personal fees from AstraZeneca, personal fees from Abbott, personal fees from Sandoz, outside the submitted work. The author reports no other conflicts of interest relevant to this work.
Références
Am J Cardiol. 2006 Dec 1;98(11):1489-92
pubmed: 17126656
Crit Care. 2020 Jul 16;24(1):442
pubmed: 32677985
Eur J Cardiothorac Surg. 2020 Jan 1;57(1):176-182
pubmed: 31155645
N Engl J Med. 2016 Oct 5;375(17):1638-1648
pubmed: 27705084
Eur J Heart Fail. 2014 Mar;16(3):281-8
pubmed: 24464960
Artif Organs. 2014 Mar;38(3):231-4
pubmed: 24147881
JACC Heart Fail. 2013 Apr;1(2):103-11
pubmed: 24621834
Cardiovasc Drugs Ther. 2013 Dec;27(6):581-90
pubmed: 23929366
J Anesth. 2019 Aug;33(4):543-550
pubmed: 31025104
J Cardiothorac Vasc Anesth. 2013 Dec;27(6):1224-32
pubmed: 24050857
N Engl J Med. 2017 May 25;376(21):2021-2031
pubmed: 28320259
Int J Cardiol. 2014 Jul 15;175(1):55-61
pubmed: 24820737
Br J Anaesth. 2016 Jul;117(1):52-8
pubmed: 27317704
JAMA. 2017 Aug 8;318(6):548-556
pubmed: 28787507
Int J Cardiol. 2017 Sep 15;243:389-395
pubmed: 28571618
Ann Intensive Care. 2019 Feb 1;9(1):24
pubmed: 30707314
Anaesthesist. 2018 May;67(5):375-379
pubmed: 29644444
Crit Care. 2016 Jul 04;20(1):208
pubmed: 27374027
Clin Pharmacokinet. 2007;46(7):535-52
pubmed: 17596101
Card Fail Rev. 2020 Jul 08;6:e19
pubmed: 32714567
Pharmacol Ther. 2007 May;114(2):184-97
pubmed: 17363065
Eur J Heart Fail. 2018 Feb;20(2):332-341
pubmed: 28990358
Cardiology. 2014;128(2):195-201
pubmed: 24751462
Herz. 2008 Jul;33(5):368-73
pubmed: 18773157
J Cardiovasc Pharmacol. 2018 Jan;71(1):1-9
pubmed: 29076887
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2009 Mar;11(3):304-11
pubmed: 19158152
Expert Rev Cardiovasc Ther. 2004 Jan;2(1):9-19
pubmed: 15038409
ASAIO J. 2013 Nov-Dec;59(6):554-7
pubmed: 24172260
Eur J Heart Fail. 2016 Jan;18(1):8-27
pubmed: 26548803
Int J Cardiol. 2008 Jul 4;127(2):284-7
pubmed: 17643519
Crit Care Med. 2007 Dec;35(12):2732-9
pubmed: 17893627
J Am Coll Cardiol. 2000 Nov 15;36(6):1903-12
pubmed: 11092663
Int J Cardiol. 2018 Dec 1;272:255-259
pubmed: 30131229
Expert Rev Cardiovasc Ther. 2021 Apr;19(4):325-335
pubmed: 33739204
Cardiol J. 2016;23(6):616-617
pubmed: 27976790
Med Intensiva (Engl Ed). 2018 Oct;42(7):409-415
pubmed: 29126662
N Engl J Med. 2017 May 25;376(21):2032-2042
pubmed: 28316276
Int J Cardiol. 2008 Aug 18;128(2):214-7
pubmed: 17643535
Intensive Care Med. 2019 Oct;45(10):1392-1400
pubmed: 31428804
Int J Cardiol. 2016 Sep 1;218:150-157
pubmed: 27232927
Crit Care Med. 2009 Dec;37(12):3017-23
pubmed: 19661807
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2769-78
pubmed: 24814488
ESC Heart Fail. 2019 Feb;6(1):174-181
pubmed: 30378288
PLoS One. 2013 Aug 15;8(8):e71659
pubmed: 23977106
Artif Organs. 2021 Jul;45(7):717-725
pubmed: 33377185
J Cardiothorac Vasc Anesth. 2016 Dec;30(6):1449-1453
pubmed: 27495966
J Am Heart Assoc. 2018 Aug 21;7(16):e008455
pubmed: 30369310
Eur J Heart Fail. 2010 Apr;12(4):404-10
pubmed: 20335355
Int J Cardiol. 2018 Jan 15;251:22-31
pubmed: 29126653
Intensive Care Med. 2011 Feb;37(2):290-301
pubmed: 21086112
Lancet. 2002 Jul 20;360(9328):196-202
pubmed: 12133653
J Cardiovasc Pharmacol. 2019 Nov;74(5):389-399
pubmed: 31730560
Eur J Heart Fail. 2014 Aug;16(8):898-906
pubmed: 24920349
Cochrane Database Syst Rev. 2018 Jan 29;1:CD009669
pubmed: 29376560
Eur J Heart Fail. 2006 Nov;8(7):723-8
pubmed: 16492404
Crit Care Med. 2008 Aug;36(8):2257-66
pubmed: 18664782
Drugs. 2001;61(5):613-27; discussion 628-9
pubmed: 11368286
Circulation. 2000 Oct 31;102(18):2222-7
pubmed: 11056096
Acute Card Care. 2008;10(1):49-57
pubmed: 17924229
J Am Coll Cardiol. 2004 Jun 16;43(12):2177-82
pubmed: 15193677
Eur J Heart Fail. 2018 Jul;20(7):1128-1136
pubmed: 29405611
Pulm Circ. 2018 Jul-Sep;8(3):2045894018790905
pubmed: 29979110
Vasc Health Risk Manag. 2010 Sep 07;6:657-63
pubmed: 20859537
Clin Pharmacokinet. 2007;46(3):235-46
pubmed: 17328582
Crit Care Med. 2012 Feb;40(2):634-46
pubmed: 21963578
Crit Care. 2010;14(2):201
pubmed: 20497611
Eur J Heart Fail. 2020 Aug;22(8):1315-1341
pubmed: 32469155
Life Sci. 2017 Sep 1;184:30-36
pubmed: 28689804
J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1415-25
pubmed: 26275522
Eur Heart J. 2002 Sep;23(18):1422-32
pubmed: 12208222
J Thorac Cardiovasc Surg. 2020 Jun;159(6):2302-2309.e6
pubmed: 31358329
J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2112-2119
pubmed: 29748076
Am Heart J. 2005 Sep;150(3):563-8
pubmed: 16169341
Eur J Heart Fail. 2013 May;15(5):565-72
pubmed: 23288914
Crit Care. 2017 Oct 19;21(1):252
pubmed: 29047417
J Crit Care. 2015 Aug;30(4):859.e1-6
pubmed: 25837801
Ann Intern Med. 2008 Sep 2;149(5):365-7
pubmed: 18765717
JAMA. 2007 May 2;297(17):1883-91
pubmed: 17473298